Background: Brain-derived neurotrophic factor (BDNF) is involved in cardiovascular 23 diseases as well as skeletal muscle energy metabolism and depression. We investigated 24 whether serum BDNF level was associated with prognosis in patients with heart failure 25 (HF). 26
symptoms were assessed using the Patient Health Questionnaire (PHQ-9). The PHQ-9 121 is a nine-item self-report measure of depressive symptoms using 0-to-3 scales, 122 established for the screening of depression in various populations. 18 
123
The left ventricular (LV) end-diastolic dimension (EDD) was measured in the 124 parasternal long axis view by transthoracic echocardiography. The LV ejection fraction 125 (LVEF) was calculated from the apical four-and two-chamber views according to the 126 biplane Simpson's method. 19 Cardiopulmonary exercise testing was performed using an 127 upright electromechanical bicycle ergometer (Aerobike 75XLII, Combi Wellness, 128
Tokyo) with a ramp protocol as described. 20 Briefly, after 3 min of unloaded cycling, 129 the exercise load was increased in 10-15 Watt/min increments to symptom-limited 130 maximal work. Minute ventilation (VE), oxygen capacity (VO 2 ), and carbon dioxide 131 manufacturer's protocol as described; 23 its detection limit was 20 pg/mL. To ensure 145 accurate measurements, all of the samples were analyzed in duplicate by investigators 146 blinded to clinical information. The inter-and intra-assay coefficients of variation (CV) 147 were 6.1% and 2.3%, respectively. 148 Plasma B-type natriuretic peptide (BNP) was measured by a chemiluminescence 149 immunoassay (CLIA) Kit (Architect BNP-JP; normal reference values, 18.4 pg/mL) in 150 an automated analyzer (Architect, Abbott Japan, Tokyo). The Architect BNP assay was 151 validated as described. 24 The limit of detection (LOD) of the assay was 5.8 pg/mL. The 152 within-run and total CVs were 2.4 and 3.4%, respectively. Linearity was acceptable 153 with recoveries within 5.0% of the target values over a concentration range of 429-2894 154 pg/mL. Our comparison of the Architect BNP-JP assay results with those of another 155 chemiluminescent enzyme immunoassay (CLEIA) (MI02 Shionogi BNP kit; Shionogi, 156 Japan) by the Passing-Bablok method resulted in slopes ranging from 1 We used a univariate linear model to determine the correlation between serum 193 BDNF levels and variables. Serum BDNF and plasma BNP levels were compared for 194 their ability to predict adverse outcomes of HF by a receiver operating characteristic 195 curve (ROC) analysis. The optimal ROC curve cut-off value for the prediction of 196 adverse outcomes was chosen as the value maximizing sensitivity plus specificity. To 197 determine whether serum BDNF levels were incremental prognostic markers in addition 198 to plasma BNP, we compared the areas under the ROC curve (AUC) of these variables 199 using the DeLong algorithm. 26 DeLong's method is a different approach from 200
Hanley's 27 to estimate the area under the ROC curve (c-index) regarding the estimation 201 of variance. Since the variance was derived from the assumption of two underlying 202 negative exponential distributions in Hanley's approach, it is known that Hanley's 203 approach can underestimate the variance when the AUC is close to 0.5 and can 204 overestimate it when the AUC is close to 1.0. 27 We thus selected DeLong's approach in 205 the present study. 206
We calculated Kaplan-Meier survival plots from baseline to the time of all 207 cardiac death or rehospitalization due to worsening HF, and we used the log-rank test to 208 compare the results. Univariate and multivariate analyses with the Cox proportional 209 hazard regression model were used to determine significant predictors of all cardiac 210 death and HF rehospitalization. Variables that were significant with a P-value < 0.01 in 211 the univariate analyses including NYHA, log BNP, and BDNF values were entered into 212 the multivariate Cox proportional hazard analysis which was adjusted for age and 213 gender. Peak VO 2 , AT, and log VE/VCO 2 slope data were excluded from the 214 multivariate analysis to avoid problems related to multicollinearity, because these with our previous study. 14 We also selected variables in the multivariate Cox model 217 based on the stepwise forward selection method due to the small number of events in 218 this study. All analyses were performed using JMP 10.0.2 (SAS Institute, Cary, NC). 219
The differences were considered significant when P-values were < 0.05. 220
221

RESULTS 222
Patients' Characteristics 223
The clinical characteristics of the study patients are summarized in Table 2 four patients (6%) were identified to be in a clinically significant depressive state. The 232 mean LVEF was 34.7±12.7%, and the mean peak VO 2 was 14.0±3.9 mL/kg/min. 233
Angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II type I receptor 234 antagonists (ARBs) were used in 89% of the patients, β-blockers in 96%, and 235 spironolactone in 60%. The mean serum BDNF level in the HF patients was 19.0±5.6 236 ng/mL. 237
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In the univariate linear model, the patients' serum BDNF levels were 240 significantly associated with their peak VO 2 (β-coefficient 0.547, P=0.003), AT (β-241 coefficient 0.929, P=0.004), and log VE/VCO 2 slope (β-coefficient −10.15, P=0.005), 242 but not age, gender, BMI, LVEDD, LVEF, eGFR, and plasma BNP levels ( Table 1) . 243
There was no significant association between serum BDNF levels and depressive status 244 according to PHQ-9 scores (β-coefficient −0.099, P=0.586). Moreover, there was no 245 significant association between serum BDNF levels and the change in peak VO 2 from 246 baseline until the end of their follow-ups (β-coefficient 0.410, P=0.233) among the 19 247 patients who performed the exercise pulmonary test repeatedly after their enrollment. 248
To assess the role of serum BDNF in adherence to exercise training, we obtained 249 data regarding each patient's participation in cardiac rehabilitation from their exercise 250 diaries. One session of cardiac rehabilitation included 30 min of aerobic exercise by a 251 cycle ergometer. Patients who participated in more than one session per week 252 throughout the follow-up period were defined as adherent in cardiac rehabilitation. As a 253 result, 25 patients (43%) were considered adherent. There was no significant difference 254 in serum BDNF levels between the adherent and non-adherent patients (19.0±5.5 vs. 255 19.1±5.7 ng/mL, P=0.945). In contrast, the patients' serum BDNF levels were 256 negatively associated with the number of sessions completed weekly (β-coefficient 257 −0.548, P=0.047). 258 259
Serum BDNF Levels Predict Adverse Outcomes 260
During the median follow-up of 20.3 months (IQR 11.5-22.8 months), there 261 were 19 (32%) adverse events including eight cardiac deaths and 11 rehospitalizations 262 due to worsening HF. Of these, the death of five patients was due to HF and that of three patients was sudden death. In addition, three patients (5%) had a new onset of 264 stroke. None of the studied patients was lost within the follow-up period. The variables 265 to predict adverse outcomes were identified by the univariate (Table 3 ) and multivariate 266
Cox proportional hazard analyses ( Table 4) . 267
In the univariate analysis, serum BDNF was significantly associated with all 268 cardiac death and HF rehospitalization [per SD increase: hazard ratio (HR) 0.47; 95% 269 confidence interval (CI) 0.29-0.75, P=0.001]. The NYHA functional class, LVEDD, 270 LVEF, peak VO 2 , AT, log VE/VCO 2 slope, and log BNP were also related to adverse 271 outcomes. The multivariate analysis revealed that among these variables, the serum 272 BDNF level and log BNP were independent predictors of adverse outcomes. The results 273 based on the stepwise forward selection method showed that the NYHA functional class, 274 log BNP, and BDNF were significant prognostic factors, and these results were 275 consistent with the first model, which included all potential candidates as covariates 276 (Table 4) . performing value of serum BDNF (17.4 ng/mL) to predict adverse events was 288 associated with 75% sensitivity, 79% specificity, 60% positive predictive values and 289 85% negative predictive values. This tended to be a slightly weaker performance than 290 that observed for plasma BNP with 85% sensitivity, 71% specificity, 60% positive 291 predictive value, and 90% negative predictive value. Adverse events occurred 292 significantly more frequently in the low (< 17.4 ng/mL) BDNF group compared to the 293 high (≥ 17.4 ng/mL) BDNF group (66% vs. 16%, P<0.001) (Fig. 2) . 294
295
DISCUSSION 296
The major finding of the present study was that lower serum BDNF levels were 297 associated with a higher incidence of adverse outcomes including all cardiac death and 298 HF rehospitalization among HF patients. Importantly, this is the first report to 299 demonstrate that the serum BDNF level was an independent prognostic factor for 300 adverse events by a multivariate Cox proportional hazard analysis. 301 302
Role of BDNF in Lowered Exercise Capacity in HF Patients 303
The present results showed a significant positive association between the serum 304 BDNF level and exercise capacity measured as the peak VO 2 , AT, and VE/VCO 2 slope. 305
These findings were consistent with those of our previous study. 14 Qualitative 306 abnormalities in skeletal muscles' energy metabolism are well known to determine the 307 exercise capacity in HF patients. 2,4 BDNF was shown to be produced in skeletal muscle, 308 and it is increased by muscle contractions to enhance fat oxidation in an AMPK-309 dependent fashion, which can regulate glucose and fatty acid metabolism. 12, 28 In 310 addition, we recently demonstrated that intramyocellular lipid is increased in the These findings suggest that serum BDNF can be a useful marker for exercise 314 capacity in HF patients, reflecting impaired fatty acid metabolism in the skeletal muscle. 315
In the present study, the change in peak VO 2 from baseline did not correlate with the 316 serum BDNF level in the limited patients, but further study is needed to determine 317 whether serum BDNF predicts the future exercise capacity in HF patients. In contrast, 318 there was a negative association between serum BDNF levels and the number of 319 completed exercise sessions, suggesting that patients with low BDNF levels may need 320 more intensive exercise training than those with high BDNF levels. 321 322
Predictive Value of Serum BDNF for Prognosis in HF Patients 323
Our results demonstrated the role of serum BDNF as a prognostic marker in HF. 324
Jiang et al. reported that multiple cardiovascular risk factors were associated with the 325 plasma BDNF level in patients with angina pectoris, and that low plasma BDNF was 326 related to future coronary events and mortality in these patients. 11 To our knowledge, 327 the present study is the first to demonstrate the predictive role of BDNF in HF. Since we 328 found that serum BDNF levels were associated with cardiopulmonary exercise variables, 329
these prognostic values of BDNF may be partly explained by a surrogate marker for 330 exercise capacity. Novel biomarkers reflective of ventricular remodeling and fibrosis 331 have been reported as an incremental prognostic value; 30 however, potential biomarkers 332 that reflect skeletal muscle abnormalities and exercise capacity have not been 333 investigated, to our knowledge.
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Even after adjustments for powerful prognostic variables including the NYHA 335 functional class and plasma BNP, we observed that the serum BDNF level was an 336 independent predictor of adverse cardiac events. These findings suggest that 337 measurements of serum BDNF could provide further information about the prognosis in 338 HF. In addition, the optimal cutoff value of BDNF determined by the ROC analysis had 339 a prognostic ability similar to that of BNP, suggesting that serum BDNF could be a 340 novel marker in addition to plasma BNP, which is the first-line biomarker for risk 341 stratification in HF. 16 342 343
Role of BDNF in Depressive Symptoms and Adherence to Exercise Training in HF 344
Circulating and hippocampal BDNF levels in patients with major depression 345 have been reported to be lower and associated with this disease severity. 31, 32 In the 346 present study, however, there was no association between serum BDNF and depressive 347 symptoms according to PHQ-9 scores. This discrepant result may be due to the 348 relatively small number of patients who were in a clinically significant depressive state 349 (6%). On the other hand, higher serum BDNF levels were reported to protect against the 350 future occurrence of dementia in the offspring of participants in the Framingham study. 9 351
Cognitive impairment is prevalent among HF patients and is associated with increased 352 mortality risk, 33 and it was also reported to affect poor treatment adherence in HF. 34 In 353 the present study, we investigated the role of BDNF in adherence to exercise training, 354 and we found that there was no difference in serum BDNF levels between the adherent 355 and non-adherent patients, suggesting that serum BDNF levels may have a minor role in 356 the adherence to exercise training in HF. 357
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Study Limitations 359
There are several potential limitations which should be acknowledged in this 360 study. First, the present study was categorized as a prognostic factor research, not 361 prognostic model research and acknowledged the lack of information regarding model 362 validation and calibration as a potential limitation. 35 Furthermore, the relatively small 363 number of studied subjects limits the statistical power for detecting the prognostic value 364 of serum BDNF levels. Therefore, a study on a larger scale is warranted to confirm the 365 relationship between worse prognosis and decreased serum BDNF levels in HF patients. 366
Second, an accurate investigation for a new biomarker has never been performed by 367 using specific statistical tests including discrimination, calibration, and reclassification 368 analyses as recommended. 36, 37 Moreover, there was no control group in the present 369 study. Third, there were no data about cognitive function, daily physical activity, or 370 medication adherence. Finally, the sources of serum BDNF are skeletal muscle, heart, 371 and brain, which could not be identified here. Despite these limitations, our observation 372 that serum BDNF can predict the prognosis in HF patients is unique and had not been 373 reported previously. 374 375
Conclusions 376
Decreased serum BDNF levels were related to all cardiac death and HF 377 readmission in HF patients. Serum BDNF may be a promising biomarker to predict the 378 adverse outcomes in HF. Further studies are needed to demonstrate the prognostic 379 incremental value of BDNF compared to the standard cardiovascular biomarkers and to 380 determine the cost-effectiveness of its measurement in patients with HF. 381
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